...
首页> 外文期刊>The journal of clinical hypertension. >Safety and tolerability of the direct renin inhibitor aliskiren in combination with angiotensin receptor blockers and thiazide diuretics: a pooled analysis of clinical experience of 12,942 patients.
【24h】

Safety and tolerability of the direct renin inhibitor aliskiren in combination with angiotensin receptor blockers and thiazide diuretics: a pooled analysis of clinical experience of 12,942 patients.

机译:直接肾素抑制剂阿利吉仑与血管紧张素受体阻滞剂和噻嗪类利尿剂合用的安全性和耐受性:汇总分析的12,942例患者的临床经验。

获取原文
获取原文并翻译 | 示例
           

摘要

Combinations of the direct renin inhibitor aliskiren with angiotensin receptor blockers (ARBs) or diuretics are effective therapeutic regimens for the treatment of hypertension. A large database of safety information has become available during the past several years with aliskiren in combination trials. Data were pooled from 9 short-term (8-week) and 4 longer-term (26- to 52-week) randomized controlled trials of aliskiren in patients with hypertension. Adverse event (AE) rates were assessed for aliskiren combination therapy compared with component monotherapies. In short-term studies, overall AE rates were similar for patients receiving aliskiren/valsartan or aliskiren/diuretic combinations (32.2%-39.8%) and those receiving the component monotherapies (30.0%-39.6%). In longer-term studies, AE rates with aliskiren/losartan (55.5%) and aliskiren/diuretic (45.0%) combination therapy were similar to those with losartan (53.9%) and diuretic (48.9%) alone. Angioedema and hyperkalemia occurred in similar proportions of patients taking combination therapies vs monotherapy. The safety and tolerability profile of aliskiren in combination with the ARBs valsartan or losartan, or diuretic, is similar to aliskiren, ARBs, or diuretics alone.
机译:直接肾素抑制剂阿利吉仑与血管紧张素受体阻滞剂(ARB)或利尿剂的组合是治疗高血压的有效治疗方案。在过去的几年中,与阿利吉仑一起进行的联合试验已经建立了庞大的安全信息数据库。数据来自9项短期(8周)和4项长期(26至52周)的阿利吉仑对高血压患者的随机对照试验。评估阿利吉仑联合疗法与单药疗法相比的不良事件发生率。在短期研究中,接受阿利吉仑/缬沙坦或阿利吉仑/利尿剂联合治疗的患者(32.2%-39.8%)和接受单一疗法的患者(30.0%-39.6%)的总AE率相似。在长期研究中,阿利吉仑/氯沙坦(55.5%)和阿利吉仑/利尿剂(45.0%)联合治疗的不良事件发生率与单独使用氯沙坦(53.9%)和利尿剂(48.9%)的患者相似。联合治疗与单药治疗的患者发生血管水肿和高钾血症的比例相似。阿利吉仑与缬沙坦或氯沙坦或利尿剂ARB联合使用的安全性和耐受性类似于阿利吉仑,ARB或利尿剂单独使用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号